Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Cited by (1,051)

Items 1,001–1,051 of 1,051

1. Characterizing the ecological and evolutionary dynamics of cancer
   Nastaran Zahir, Ruping Sun, Daniel Gallahan, Robert A. Gatenby, Christina N. Curtis · 2020 · Nature Genetics
2. PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
   Stenehjem, David, Tran, Dao, Nkrumah, Michael, Gupta, Shilpa · 2018 · OncoTargets and Therapy
3. Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy
   Makuku, Rangarirai, Khalili, Neda, Razi, Sepideh, Keshavarz-Fathi, Mahsa, Rezaei, Nima · 2021 · Journal of Immunology Research
4. Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer
   Kim, Hye In, Kim, Mijin, Lee, Se-Hoon, Park, So Young, Kim, Young Nam, Kim, Hosu, Jeon, Min Ji, Kim, Tae Yong, Kim, Sun Wook, Kim, Won Bae et al. · 2018 · OncoImmunology
5. Understanding mutagenesis through delineation of mutational signatures in human cancer
   Petljak, Mia, Alexandrov, Ludmil B. · 2016 · Carcinogenesis
6. Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
   Yu, Chune, Liu, Xiaowei, Yang, Jiqiao, Zhang, Min, Jin, Hongyu, Ma, Xuelei, Shi, Hubing · 2019 · Frontiers in Immunology
7. Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities
   Roybal, Kole T., Lim, Wendell A. · 2017 · Annual Review of Immunology
8. Portrait of a cancer: mutational signature analyses for cancer diagnostics
   Van Hoeck, Arne, Tjoonk, Niels H., van Boxtel, Ruben, Cuppen, Edwin · 2019 · BMC Cancer
9. KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
   Friedlaender, Alex, Drilon, Alexander, Weiss, Glen J., Banna, Giuseppe L., Addeo, Alfredo · 2020 · Cancer Treatment Reviews
10. Hypoxia and the phenomenon of immune exclusion
    Pietrobon, Violena, Marincola, Francesco M. · 2021 · Journal of Translational Medicine
11. Circulating tumour DNA (CtDNA) as a liquid biopsy for melanoma
    Calapre, Leslie, Warburton, Lydia, Millward, Michael, Ziman, Mel, Gray, Elin S. · 2017 · Cancer Letters
12. PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations
    Scheel, Andreas H., Ansén, Sascha, Schultheis, Anne M., Scheffler, Matthias, Fischer, Rieke N., Michels, Sebastian, Hellmich, Martin, George, Julie, Zander, Thomas, Brockmann, Michael et al. · 2016 · OncoImmunology
13. The role of biomarkers in personalized immunotherapy
    Sankar, Kamya, Ye, Jing Christine, Li, Zihai, Zheng, Lei, Song, Wenru, Hu-Lieskovan, Siwen · 2022 · Biomarker Research
14. In vitro immunotherapy potency assays using real-time cell analysis
    Cerignoli, Fabio, Abassi, Yama A., Lamarche, Brandon J., Guenther, Garret, Santa Ana, David, Guimet, Diana, Zhang, Wen, Zhang, Jing, Xi, Biao · 2018 · PLOS ONE
15. Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study
    Gogas, H., Dréno, B., Larkin, J., Demidov, L., Stroyakovskiy, D., Eroglu, Z., Francesco Ferrucci, P., Pigozzo, J., Rutkowski, P., Mackiewicz, J. et al. · 2021 · Annals of Oncology
16. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy
    Soundararajan, Rama, Fradette, Jared, Konen, Jessica, Moulder, Stacy, Zhang, Xiang, Gibbons, Don, Varadarajan, Navin, Wistuba, Ignacio, Tripathy, Debasish, Bernatchez, Chantale et al. · 2019 · Cancers
17. Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency
    Davies, Helen, Morganella, Sandro, Purdie, Colin A., Jang, Se Jin, Borgen, Elin, Russnes, Hege, Glodzik, Dominik, Zou, Xueqing, Viari, Alain, Richardson, Andrea L. et al. · 2017 · Cancer Research
18. KRAS G12C–Mutant Non–Small Cell Lung Cancer
    Veluswamy, Rajwanth, Mack, Philip C., Houldsworth, Jane, Elkhouly, Ehab, Hirsch, Fred R. · 2021 · The Journal of Molecular Diagnostics
19. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
    Yu, Jiayi, Yan, Junya, Guo, Qian, Chi, Zhihong, Tang, Bixia, Zheng, Bin, Yu, Jinyu, Yin, Ting, Cheng, Zhiyuan, Wu, Xiaowen et al. · 2019 · Clinical Cancer Research
20. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses
    Lo, Jennifer A., Kawakubo, Masayoshi, Juneja, Vikram R., Su, Mack Y., Erlich, Tal H., LaFleur, Martin W., Kemeny, Lajos V., Rashid, Mamunur, Malehmir, Mohsen, Rabi, S. Alireza et al. · 2021 · Science Translational Medicine
21. Adoptive T-cell therapy for cancer: the era of engineered T cells
    Bonini, Chiara, Mondino, Anna · 2015 · European Journal of Immunology
22. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer
    Alemohammad, Hajar, Najafzadeh, Basira, Asadzadeh, Zahra, Baghbanzadeh, Amir, Ghorbaninezhad, Farid, Najafzadeh, Arezoo, Safarpour, Hossein, Bernardini, Renato, Brunetti, Oronzo, Sonnessa, Margherita et al. · 2022 · Biomedicine & Pharmacotherapy
23. Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors
    Berland, Léa, Heeke, Simon, Humbert, Olivier, Macocco, Adam, Long-Mira, Elodie, Lassalle, Sandra, Lespinet-Fabre, Virginie, Lalvée, Salomé, Bordone, Olivier, Cohen, Charlotte et al. · 2019 · Journal of Thoracic Disease
24. Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic <i>KRAS</i> and <i>ERBB2</i> ( <i>Her2</i> ) Driver Mutations
    Veatch, Joshua R., Jesernig, Brenda L., Kargl, Julia, Fitzgibbon, Matthew, Lee, Sylvia M., Baik, Christina, Martins, Renato, Houghton, A. McGarry, Riddell, Stanley R. · 2019 · Cancer Immunology Research
25. Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma
    Arakawa, Akiko, Vollmer, Sigrid, Tietze, Julia, Galinski, Adrian, Heppt, Markus V., Bürdek, Maja, Berking, Carola, Prinz, Jörg C. · 2019 · Frontiers in Immunology
26. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
    Shi, Congqi, Qin, Kaiyu, Lin, Anqi, Jiang, Aimin, Cheng, Quan, Liu, Zaoqu, Zhang, Jian, Luo, Peng · 2022 · Journal of Experimental &amp; Clinical Cancer Research
27. Entinostat induces antitumor immune responses through immune editing of tumor neoantigens
    Truong, Andrew S., Zhou, Mi, Krishnan, Bhavani, Utsumi, Takanobu, Manocha, Ujjawal, Stewart, Kyle G., Beck, Wolfgang, Rose, Tracy L., Milowsky, Matthew I., He, Xiaping et al. · 2021 · Journal of Clinical Investigation
28. Trial watch: immune checkpoint blockers for cancer therapy
    Vanpouille-Box, Claire, Lhuillier, Claire, Bezu, Lucillia, Aranda, Fernando, Yamazaki, Takahiro, Kepp, Oliver, Fucikova, Jitka, Spisek, Radek, Demaria, Sandra, Formenti, Silvia C. et al. · 2017 · OncoImmunology
29. Genome Sequencing during a Patient’s Journey through Cancer
    Nangalia, Jyoti, Campbell, Peter J. · 2019 · New England Journal of Medicine
30. Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
    Tremblay-LeMay, Rosemarie, Rastgoo, Nasrin, Chang, Hong · 2018 · Journal of Hematology &amp; Oncology
31. Measuring tumor mutation burden in non-small cell lung cancer: Tissue versus liquid biopsy
    Fenizia, Francesca, Pasquale, Raffaella, Roma, Cristin, Bergantino, Francesca, Iannaccone, Alessia, Normanno, Nicola · 2018 · Translational Lung Cancer Research
32. HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy
    Jiang, Qinqin, Braun, David A., Clauser, Karl R., Ramesh, Vijyendra, Shirole, Nitin H., Duke-Cohan, Joseph E., Nabilsi, Nancy, Kramer, Nicholas J., Forman, Cleo, Lippincott, Isabelle E. et al. · 2025 · Cell
33. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4
    van den Bulk, Jitske, Verdegaal, Els M. E., Ruano, Dina, Ijsselsteijn, Marieke E., Visser, Marten, van der Breggen, Ruud, Duhen, Thomas, van der Ploeg, Manon, de Vries, Natasja L., Oosting, Jan et al. · 2019 · Genome Medicine
34. Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
    D’Angelo, Sandra P., Richards, Allison L., Conley, Anthony P., Woo, Hyung Jun, Dickson, Mark A., Gounder, Mrinal, Kelly, Ciara, Keohan, Mary Louise, Movva, Sujana, Thornton, Katherine et al. · 2022 · Nature Communications
35. KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma
    Frost, Nikolaj, Kollmeier, Jens, Vollbrecht, Claudia, Grah, Christian, Matthes, Burkhard, Pultermann, Dennis, von Laffert, Maximilian, Lüders, Heike, Olive, Elisabeth, Raspe, Matthias et al. · 2021 · Translational Lung Cancer Research
36. Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma
    Bassaganyas, Laia, Pinyol, Roser, Esteban-Fabró, Roger, Torrens, Laura, Torrecilla, Sara, Willoughby, Catherine E., Franch-Expósito, Sebastià, Vila-Casadesús, Maria, Salaverria, Itziar, Montal, Robert et al. · 2020 · Clinical Cancer Research
37. Identification of responders to immune checkpoint therapy: Which biomarkers have the highest value?
    Liebl, M.C., Hofmann, T.G. · 2019 · Journal of the European Academy of Dermatology and Venereology
38. Biomarkers for Response to Immune Checkpoint Blockade
    Ganesan, Shridar, Mehnert, Janice · 2020 · Annual Review of Cancer Biology
39. Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
    Lucas, Minke W., Versluis, Judith M., Rozeman, Elisa A., Blank, Christian U. · 2023 · Nature Reviews Clinical Oncology
40. Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma
    Hurkmans, Daan P, Jensen, Christina, Koolen, Stijn L W, Aerts, Joachim, Karsdal, Morten Asser, Mathijssen, Ron H J, Willumsen, Nicholas · 2020 · Journal for ImmunoTherapy of Cancer
41. Refining patient selection for breast cancer immunotherapy: beyond PD-L1
    Kossai, M., Radosevic-Robin, N., Penault-Llorca, F. · 2021 · ESMO Open
42. Deep learning in digital pathology for personalized treatment plans of cancer patients
    Wen, Zhuoyu, Wang, Shidan, Yang, Donghan M., Xie, Yang, Chen, Mingyi, Bishop, Justin, Xiao, Guanghua · 2023 · Seminars in Diagnostic Pathology
43. Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy
    Vigneron, Nathalie, Abi Habib, Joanna, Van den Eynde, Benoit J. · 2017 · Trends in Cancer
44. Sunitinib inhibits PD-L1 expression in osteosarcoma by targeting STAT3 and remodels the immune system in tumor-bearing mice
    Duan, Xian Liang, Guo, Jian Ping, Li, Fan, Xiu, Chao, Wang, Hua · 2020 · Future Oncology
45. ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
    Kyte, J. A., Røssevold, A., Falk, R. S., Naume, B. · 2020 · Journal of Translational Medicine
46. TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Lin, Anqi, Zhang, Hongman, Meng, Hui, Deng, Ze, Gu, Tianqi, Luo, Peng, Zhang, Jian · 2021 · Frontiers in Immunology
47. Comprehensive analysis of DNA damage repair deficiency in 10,284 pan–cancer study
    Xiao, Yanni, Lu, Di, Lei, Mingxing, Xie, Wenzhuan, Chen, Yaoxu, Zheng, Yating, Wang, Chunli, Zhao, Jing, Zhu, Zhen, Zhao, Xiaochen et al. · 2021 · Annals of Translational Medicine
48. Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors
    Zhang, Xin, Li, Huiqin, Lv, Xiupeng, Hu, Li, Li, Wen, Zi, Meiting, He, Yonghan · 2022 · Life
49. Deep learning analysis of histopathological images predicts immunotherapy prognosis and reveals tumour microenvironment features in non-small cell lung cancer
    Wang, Youyu, Ju, Xueming, Hua, Rong, Chen, Ji, Dai, Xiaoqin, Liu, Lunxu, Wang, Guifang, Bai, Yifeng, Hu, Honglin, Li, Xiaohua · 2024 · British Journal of Cancer
50. Group 1 <scp>CD1</scp>‐restricted T cells and the pathophysiological implications of self‐lipid antigen recognition
    Dellabona, P., Consonni, M., de Lalla, C., Casorati, G. · 2015 · Tissue Antigens
51. HLA-A*26 is correlated with response to nivolumab in Japanese melanoma patients
    Ishida, Yoshihiro, Otsuka, Atsushi, Tanaka, Hidenori, Levesque, Mitchell P., Dummer, Reinhard, Kabashima, Kenji · 2017 · Journal of Investigative Dermatology